Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01099644 · ClinicalTrials.gov registry record · Phase 1

Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum

A Phase 1 study, sponsored by Y-mAbs Therapeutics.

Terminated
Registry status
Phase 1
Development phase
54
Enrollment target

NCT01099644 is a Phase 1 study that was terminated before completion, run by Y-mAbs Therapeutics. The registered enrollment target is 54 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01099644, a Phase 1 study, was terminated before completion, sponsored by Y-mAbs Therapeutics.

TERMINATED
Registry status
Phase 1
Development phase
54 participants
Enrollment target

Study Summary

A phase I study of Intraperitoneal Radioimmunotherapy with 131 I-omburtamab in patients \>1 year of age with desmoplastic small round cell tumors and other solid tumors involving the peritoneum.

Interventions

  • BIOLOGICAL 131 I-8H9

Trial Details

FieldValue
Enrollment Target 54 participants
Start Date 2010-04
Est. Completion 2019-06-11
Phase Phase 1

Sponsor

Y-mAbs Therapeutics

11 total trials

What the Registry Record Tells You About NCT01099644

The ClinicalTrials.gov registry entry for NCT01099644 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Y-mAbs Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which 131 I-8H9 is the first listed.

NCT01099644 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01099644 about?

NCT01099644 is a clinical study titled "Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum". A phase I study of Intraperitoneal Radioimmunotherapy with 131 I-omburtamab in patients \>1 year of age with desmoplastic small round cell tumors and other solid tumors involving the peritoneum.

What is the current status of trial NCT01099644?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2010-04. Estimated completion is 2019-06-11.

What interventions are being tested in trial NCT01099644?

The interventions under investigation include: 131 I-8H9 (BIOLOGICAL).

Who is sponsoring clinical trial NCT01099644?

This trial is sponsored by Y-mAbs Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.